Extended-spectrum ß-lactamase-producing and third-generation cephalosporin-resistant Enterobacteriaceae in children: Trends in the United States, 1999-2011

Journal of the Pediatric Infectious Diseases Society

Volumn 3, Issue 4, 2014, Pages 320-328

  Logan, Latania K ^a,b,c   Braykov, Nikolay P ^d,g   Weinstein, Robert A ^a,c   Laxminarayan, Ramanan ^d,e,f  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Jr Hospital of Cook County   (United States)

^d Economics and Policy   (United States)

^e PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^f PRINCETON UNIVERSITY   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

Antibacterial agents; Child; Drug resistance; Enterobacteriaceae infections; Epidemiology; Lactamases

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; COTRIMOXAZOLE; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; UNITED STATES;

EID: 84928887572     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu010     Document Type: Article

References (43)

1. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11:315-7.
2. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54:969-76.
3. Jacoby GA, Munoz-Price L. The new ß-lactamases. N Engl J Med 2005; 352:380-91.
4. Bush K, Fisher J. Epidemiological expansion, structural studies, and clinical challenges of new ß-lactamases from gram-negative bacteria. Annu Rev Microbiol 2011; 65:455-78.
5. Ambler RP. The structure of beta-lactamases. Philosoph Transact R Soc Biol Sci 1980; 289:321-31.
6. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S. Current trends in culture-based and molecular detection of ESBL-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2012; 50:1140-6.
7. Tenover FC, Mohammed MJ, Gorton TS, Dembek ZF. Detection and reporting of organisms producing extended-spectrum ß-lactamases: Survey of laboratories in Connecticut. J Clin Microbiol 1999; 37:4065-70.
8. Thomson KS. Extended-spectrum-ß-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 2010; 48:1019-25.
9. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Sept. 16, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/ Accessed January 3, 2014.
10. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14.
11. Stone PW, Gupta A, Loughrey M, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24:601-6.
12. Ramphal R. Extended-spectrum ß-lactamases and clinical outcomes: Current data. Clin Infect Dis 2006; 42(suppl 4): S164-72.
13. Paterson DL, Bonomo RA. Extended-spectrum ß-lactamases: A clinical update. Clin Microbiol Rev 2005; 18:657-86.
14. Apisarnthanarak A, Kiratisin P, Saifon P, et al. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: A case-case-control study. Am J Infect Control 2007; 35:606-12.
15. Jhaveri R, Bronstein D, Sollod J, Kitchen C, Krogstad P. Outcome of infections with extended spectrum beta-lactamase producing organisms in children. J Pediatr Infect Dis 2008; 3:229-33.
16. Blaschke AJ, Korgenski EK, Daly JA, LaFleur B, Pavia AT, Byington CL. Extended-spectrum beta-lactamase-producing pathogens in a children's hospital: A 5-year experience. Am J Infect Control 2009; 37:435-41.
17. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115:942-9.
18. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol 2013; 34:259-68.
19. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob 2004; 3:3.
20. Klein E, Smith DL, Laxminarayan R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis 2009; 15:1925-30.
21. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: Electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 1999; 29:259-63.
22. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement ( June 2010 Update). 2010; December 29, 2011.
23. Centers for Disease Control and Prevention (CDC). Vital signs: Carbapenem-resistant Enterobacteriaceae. MMWR Morbid Mortal Wkly Rep 2013; 62:165-70.
24. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: Risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002; 23:254-60.
25. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 2008; 68:108-15.
26. Hayakawa K, Gattu S, Marchaim D, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum ß-lactamase in a large U.S. medical center. Antimicrob Agent Chemother 2013; 57:4010-8.
27. Shah AA, Hasan F, Ahmed S, Hameed A. Characteristics, epidemiology and clinical importance of emerging strains of Gramnegative bacilli producing extended-spectrum ß-lactamases. Res Microbiol 2004; 155:409-21.
28. Stürenburg E, Mack D. Extended-spectrum ß-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47:273-95.
29. Logan LK,Meltzer LA,McAuley JB, et al. for the CDC Epicenters Prevention Program. Extended-spectrum ß-lactamase-producing Enterobacteriaceae infections in children: A two-center case-case-control study of risk factors and outcomes in Chicago, Illinois. J Pediatr Infect Dis 2014; 3:312-9.
30. Logan LK. Carbapenem-resistant Enterobacteriaceae: An emerging problem in children. Clin Infect Dis 2012; 55:852-9.
31. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: A metaanalysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1862-77.
32. Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum ß-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56:641-8.
33. Chandramohan L, Revell PA. Prevalence and molecular characterization of extended-spectrum-ß-lactamase-producing Enterobacteriaceae in a pediatric patient population. Antimicrob Agent Chemother 2012; 56:4765-70.
34. Weissman SJ, Adler A, Qin X, Zerr DM. Emergence of extendedspectrum ß-lactam resistance among Escherichia coli at a US academic children's hospital is clonal at the sequence type level for CTX-M-15, but not for CMY-2. Int J Antimicrob Agents 2013; 41:414-20.
35. Cantón R, Coque TM. The CTX-M ß-lactamase pandemic. Curr Opin Microbiol 2006; 9:466-75.
36. Viau RA, Hujer AM, Marshall SH, et al. "Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio. Clin Infect Dis 2012; 54:1314-21.
37. Thurlow CJ, Prabaker K, Lin MY, et al. Anatomic sites of patient colonization and environmental contamination with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae at long-term acute care hospitals. Infect Control Hosp Epidemiol 2013; 34:56-61.
38. Prabaker K, LinMY,McNallyM, et al. Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: A multihospital study. Infect Control Hosp Epidemiol 2012; 33:1193-9.
39. Löhr IH, Rettedal S, Natås OB, Naseer U, Øymar K, Sundsfjord A. Long-term faecal carriage in infants and intra-household transmission of CTX-M-15-producing Klebsiella pneumoniae following a nosocomial outbreak. J Antimicrob Chemother 2013; 68:1043-8.
40. Kallen AJ, Beekmann SE, Limbago B, et al. Prevalence of betalactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: A survey of infectious disease physicians. Diag Microbiol Infect Dis 2011; 71:316-9.
41. Hidron AI, Edwards JRM, Patel J, et al. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcareassociated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011.
42. Diekema DJ, BootsMiller BJ, Vaughn TE, et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004; 38:78-85.
43. Karlowsky J, Jones M, Draghi D, Thornsberry C, Sahm D, Volturo G. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann ClinMicrobiol Antimicrob 2004; 3:7.